Page 1

Interim Report April - September 2021 July - September Consolidated sales during the second quarter , July to September amounted to SEK 52.5 ( 24.2 ) million . Adjusted for non - recurring sales the revenue amounted to 34.5 ( 24.2 ) MSEK , an increase of 42.6 % . A strong quarter for both our pharma sales and our sales of Covid - 19 tests Gross profit amounted to SEK 16.3 ( 10.4 ) million for the quarter , an increase of 56.4 % . ( SEK million ) Net sales Sales growth % Gross margin % EBIT Profit for the period EBIT for the quarter was SEK 5.9 ( 3.4 ) million . Earnings per share were SEK 0:18 ( 0:11 ) for the quarter . Cash flow from operating activities amounted to SEK 4.3 ( 40.0 ) million for the quarter . Cash and cash equivalents were SEK 8.0 ( 19.7 ) million at the end of the quarter . July - Sep 2021 52,46 117 31 5,93 5,35 April - September Consolidated sales during the period April - September amounted to SEK 89.1 ( 123.7 ) million . Adjusted for non recurring sales the revenue amounted to 66.1 ( 46.6 ) MSEK , an increase of 41.8 % . Gross profit for the same period amounted to SEK 34.2 ( 32.8 ) million , a decrease of 4 % . EBIT for April - September amounted to SEK 9.0 ( 15.0 ) million . Earnings per share were SEK 0:27 ( 0:50 ) for the period . Cash flow from operating activities amounted to SEK -4.2 ( 16.2 ) million during April - September . Cash and cash equivalents were SEK 8.0 ( 19.7 ) million at the end of September . July - Sep 2020 24,22 36 43 3,40 3,24 EQL PHARMA April - Sep 2021 89,12 -28 36 8,96 7,85 April - Sep 2020 April - March 2021 123,73 179,14 232 149 27 28 15,01 14,44 11,52 10,37